<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814580</url>
  </required_header>
  <id_info>
    <org_study_id>CR015040</org_study_id>
    <secondary_id>R331333PAI3022</secondary_id>
    <secondary_id>KF5503/49</secondary_id>
    <nct_id>NCT00814580</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone IR for Treatment of Acute Post-op Pain Following Elective Arthroscopic (Surgery Using a Thin Flexible Scope) Shoulder Surgery</brief_title>
  <official_title>A Randomized, Double-Blind, Multi-Center, Parallel-Group Study of Tapentadol Immediate Release (IR) Versus Oxycodone IR for the Treatment of Subjects With Acute Post-Operative Pain Following Elective Arthroscopic Shoulder Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ortho-McNeil Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gr√ºnenthal GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ortho-McNeil Janssen Scientific Affairs, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate how tapentadol immediate release (IR) and oxycodone
      IR treat moderate to severe post-operative pain after elective arthroscopic shoulder surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind (neither the patient nor the study doctor knows the name of the
      assigned study drug during the study), randomized (study drug selected by chance like
      flipping a coin), active-comparator (patient will get active drug and there is no inactive
      drug), outpatient study to evaluate efficacy and how well a patient tolerates multiple doses
      of tapentadol immediate release (IR) versus oxycodone IR for short-term moderate to severe
      post-operative pain after arthroscopic (a surgical technique whereby a doctor inserts a
      tube-like instrument into a joint to visually inspect and repair tissues) shoulder surgery.
      About 370 patients will be enrolled to either receive tapentadol IR or oxycodone IR until
      approximately 150 patients in each treatment group are enrolled. After obtaining informed
      consent, patients will have screening visit procedures to determine study eligibility. Visit
      1 (screening) may begin up to 21 days prior to surgery. Pre-operative assessments (e.g.,
      physical examinations, clinical laboratory assessments) will be conducted as part of routine
      procedures. Patients will have a urine drug test and women who are able to have children will
      have a urine pregnancy test performed as part of screening prior to the study. Height and
      weight will be taken and a sleep questionnaire will also be completed at screening. Study
      staff will conduct pre-operative teaching regarding post-operative pain including: the pain
      intensity assessment for the study (11-point numeric rating scale where 0=no pain and 10=pain
      as bad as you can imagine); descriptions of mild, moderate and severe pain; instructions for
      dosing with study medication; and completing the study diary. Eligible patients will be
      post-operative men and women who have undergone elective outpatient arthroscopic shoulder
      surgery. Patients must have received a regional interscalene (within the scalene muscles)
      nerve block as the primary anesthetic (numbing medication) during the procedure and do not
      require intravenous (through a vein) patient-controlled analgesia post-operatively. Patients
      who are expected to have moderate to severe acute post-operative pain from shoulder surgery
      and who are appropriate candidates for outpatient pain management with an oral opioid
      (narcotic) pain medication will be eligible. In addition, appropriate patients are expected
      to require oral opioid pain medication post-operatively. Patients who continue to meet all
      study criteria post-operatively will be assigned to a study drug group prior to PACU
      discharge (PACU is considered Visit 2) and will be sent home with study medication. All
      patients will be prescribed a standard regimen of cold pack application to the surgical
      shoulder. Patients will be instructed to take the first dose of study medication as their
      first oral pain medication when they have at least &quot;moderate&quot; pain (prior to discharge or at
      home). Patients will be reminded about instructions on post-operative pain that were
      discussed during the pre-operative screening visit. Patients will also be instructed to
      complete a diary assessment of their current pain intensity before taking the first dose of
      study medication. Day 1 will be the calendar day when the patient takes the first dose of
      study medication. Starting on Day 1, patients will be instructed to complete assessments in
      paper diaries each morning and evening related to pain intensity, pain relief, and
      occurrences of vomiting. All patients will be contacted by telephone by a member of the study
      staff on the day following surgery. The staff will verify that the first dose of study
      medication was taken and the baseline pain intensity assessment was recorded. All patients
      will receive a second telephone call from the study staff on Day 3. During this telephone
      call, site personnel will inquire about the patient's overall status and will reinforce diary
      compliance. If the study staff determines it is necessary, the patient will be required to
      return to the study site for an unscheduled visit. Patients may take up to 2 pills (any form)
      of acetaminophen for pain other than post-operative shoulder pain (e.g., headache, back pain)
      once per day only for up to a total of 2 days during the study. Patients who take up to 325
      mg/day aspirin as prevention for a heart condition will be permitted to enter the study and
      continue on study medication provided they are on a stable dose for at least 1 month prior to
      study entry and plan to continue the same dose during the study. Patients who complete the
      study will return to the study site for a final visit (Visit 3) on Day 7. Patients who
      discontinue early for any reason (i.e., lack of efficacy, adverse events, patient's choice)
      should contact the study staff before taking supplemental pain medication and schedule
      his/her final visit. Patients will complete a final assessment of pain intensity and pain
      relief. In addition, all patients will complete a sleep questionnaire, a Patient Global
      Impression of Change and an assessment of satisfaction with treatment. The study doctor will
      complete a Clinician Global Impression of Change and will record any medical resource
      utilization noted in the office charts (e.g., unplanned calls from the subject, unscheduled
      office visits, emergency room visits). Vital signs will be obtained and study medication will
      be collected and counted. Patients will have adverse events assessed and any changes in
      concomitant medications (other medications taken at the same time as the study medication)
      recorded. All patients will have post-study medication prescribed at the study doctor's
      discretion. A patient may elect to take supplemental pain medication to treat their
      post-operative shoulder pain at any time during the study; however, patients who take
      supplemental pain medication will be considered discontinued from the study. Patients will be
      assigned by chance equally (1:1) in a blinded (neither the patient or study doctor knows)
      fashion to get tapentadol immediate release (IR) 50 or 100 mg vs oxycodone IR 5 or 10 mg,
      every 4-6 hours as needed. Treatment is up to 7 days starting on Day 1 with one capsule of
      study medication. A &quot;re-dose&quot; is permitted and may be administered as soon as one hour after
      the first dose only. For subsequent doses, patients may take one or two capsules every 4 to 6
      hours as needed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 3 Days (72 Hours)</measure>
    <time_frame>3 Days (72 hours)</time_frame>
    <description>Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID72 was calculated as the time-weighted Sum of PID scores over 72 hours. The range of SPID72 is from -720 to 720. The higher value in SPID indicates greater pain relief.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Summary of Kaplan-Meier Estimates for Time to Achieve 50% Reduction in Pain Intensity From Baseline</measure>
    <time_frame>7 Days</time_frame>
    <description>From date of first administration of study medication to time to achieve adequate 50% reduction in pain intensity from baseline score. Censored observations included subjects who completed or discontinued from the study without a 50% reduction in pain intensity from baseline score. If a subject discontinued due to lack of efficacy (including rescue medication), the subject was censored on Day 7, 12 PM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Kaplan-Meier Estimates for Time to Achieve 30% Reduction in Pain Intensity From Baseline</measure>
    <time_frame>7 Days</time_frame>
    <description>From date of first administration of study medication to time to achieve adequate 30% reduction in pain intensity from baseline score. Censored observations included subjects who completed or discontinued from the study without a 30% reduction in pain intensity from baseline score. If a subject discontinued due to lack of efficacy (including rescue medication), the subject was censored on Day 7, 12 PM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of 30% Responder Rate (With Imputation) on Day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>The 30% responder rate was defined as the proportion of participants with a value of percentage change greater than or equal to the 30% from baseline in pain intensity at Day 3 (average of Day 3 PM and Day 4 AM). If a subject has only the Day 3 PM value or Day 4 AM value, then response rate will be based on the non-missing value. If a subject withdraws or uses rescue medication before Day 3 PM then Baseline Observation Carried Forward (BOCF) will be imputed. Last Observation Carried Forward (LOCF) may be used if no value afterward.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of 30% Responder Rate (With Imputation) on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>The 30% responder rate was defined as the proportion of participants with a value of percentage change greater than or equal to the 30% from baseline in pain intensity at Day 7 (average of Day 6 PM and Day 7 AM). If a subject has only the Day 6 PM value or Day 7 AM value, then response rate will be based on the non-missing value. If a subject withdraws or uses rescue medication before Day 6 PM then BOCF will be imputed. LOCF may be used if no value afterward.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of 50% Responder Rate (With Imputation) on Day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>The 50% responder rate was defined as the proportion of participants with a value of percentage change greater than or equal to the 50% from baseline in pain intensity at Day 3 (average of Day 3 PM and Day 4 AM). If a subject has only the Day 3 PM value or Day 4 AM value, then response rate will be based on the non-missing value. If a subject withdraws or uses rescue medication before Day 3 PM then BOCF will be imputed. LOCF may be used if no value afterward.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of 50% Responder Rate (With Imputation) on Day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>The 50% responder rate was defined as the proportion of participants with a value of percentage change greater than or equal to the 50% from baseline in pain intensity at Day 7 (average of Day 6 PM and Day 7 AM). If a subject has only the Day 6 PM value or Day 7 AM value, then response rate will be based on the non-missing value. If a subject withdraws or uses rescue medication before Day 6 PM then BOCF will be imputed. LOCF may be used if no value afterward.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 2 Days (48 Hours)</measure>
    <time_frame>2 Days (48 hours)</time_frame>
    <description>Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID48 was calculated as the time-weighted Sum of PID scores over 48 hours. The range of SPID48 is from -480 to 480. The higher value in SPID indicates greater pain relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 7 Days</measure>
    <time_frame>7 Days</time_frame>
    <description>Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID over 7 Days was calculated as the time-weighted Sum of PID scores up to Day 7, 8 AM. The range is from -1440 to 1440. The higher value in SPID indicates greater pain relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary and Analysis of Total Pain Relief (TOTPAR) (With Imputation) Over 2 Days (48 Hours)</measure>
    <time_frame>2 Days (48 hours)</time_frame>
    <description>Pain Relief was defined as a 5-point categorical scale of 0-4 (0=none, 1=A little, 2=Some, 3=A lot, 4=Complete). Total Pain Relief (TOTPAR) was calculated as the time-weighted sum over all pain relief up to hour 48. The range of TOTPAR over 2 days is from 0 to 192. A higher value in TOTPAR indicated greater pain relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary and Analysis of Total Pain Relief (TOTPAR) (With Imputation) Over 3 Days (72hours)</measure>
    <time_frame>3 Days (72hours)</time_frame>
    <description>Pain Relief was defined as a 5-point categorical scale of 0-4 (0=none, 1=A little, 2=Some, 3=A lot, 4=Complete). Total Pain Relief (TOTPAR) was calculated as the time-weighted sum over all pain relief up to hour 72. The range of TOTPAR over 3 days is from 0 to 288. A higher value in TOTPAR indicated greater pain relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary and Analysis of Total Pain Relief (TOTPAR) (With Imputation) Over 7 Days</measure>
    <time_frame>7 Days</time_frame>
    <description>Pain Relief was defined as a 5-point categorical scale of 0-4 (0=none, 1=A little, 2=Some, 3=A lot, 4=Complete). Total Pain Relief (TOTPAR) was calculated as the time-weighted sum over all pain relief up to Day 7, 8 AM. The range of TOTPAR over 7 days is from 0 to 576. A higher value in TOTPAR indicated greater pain relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary and Analysis of the Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) (With Imputation) Over 2 Days (48 Hours)</measure>
    <time_frame>2 Days (48 hours)</time_frame>
    <description>The Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) was derived from Sum of TOTPAR and SPID. The range of SPRID over 2 days is from -480 to 672. A higher value in SPRID indicated greater pain relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary and Analysis of the Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) (With Imputation) Over 3 Days (72 Hours)</measure>
    <time_frame>3 Days (72hours)</time_frame>
    <description>The Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) was derived from Sum of TOTPAR and SPID. The range of SPRID over 3 days is from -720 to 1008. A higher value in SPRID indicated greater pain relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary and Analysis of the Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) (With Imputation) Over 7 Days</measure>
    <time_frame>7 Days</time_frame>
    <description>The Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) was derived from Sum of TOTPAR and SPID. The range of SPRID over 7 days is from -1440 to 2016. A higher value in SPRID indicated greater pain relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction With Treatment</measure>
    <time_frame>7 Days</time_frame>
    <description>Treatment satisfaction was measured using a 7-point scale where 1 = very satisfied and 7 = very dissatisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) at End of Study</measure>
    <time_frame>7 Days</time_frame>
    <description>Patient Global Impression of Change (PGIC) was defined as the 7-point numeric scale, where 1=very much improved to 7=very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician Global Impression of Change (CGIC) at End of Study</measure>
    <time_frame>7 Days</time_frame>
    <description>Clinician Global Impression of Change (CGIC) was defined as the 7-point numeric scale, where 1=very much improved to 7=very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Medical Resource Utilization - Number of Calls by the Subject to Study Site Personnel</measure>
    <time_frame>7 Days</time_frame>
    <description>Information associated with contacts with a healthcare professional was collected by the investigator and study staff for all subjects throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Medical Resource Utilization - Number of Other Types of Contacts With Healthcare Professionals</measure>
    <time_frame>7 Days</time_frame>
    <description>Information associated with contacts with a healthcare professional was collected by the investigator and study staff for all subjects throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality: Trouble Falling Asleep? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</measure>
    <time_frame>Baseline and 7 Days</time_frame>
    <description>Over the past 7 days patients reported &quot;trouble falling asleep&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality: Trouble Falling Asleep? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</measure>
    <time_frame>Baseline and 7 Days</time_frame>
    <description>Over the past 7 days patients reported &quot;trouble falling asleep&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality: Wake up Several Times During Night? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</measure>
    <time_frame>Baseline and 7 Days</time_frame>
    <description>Over the past 7 days patients reported &quot;Wake up several times during night&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality: Wake up Several Times During Night? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</measure>
    <time_frame>Baseline and 7 Days</time_frame>
    <description>Over the past 7 days patients reported &quot;Wake up several times during night&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality: Trouble Staying Asleep? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</measure>
    <time_frame>Baseline and 7 Days</time_frame>
    <description>Over the past 7 days patients reported &quot;Trouble staying asleep&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality: Trouble Staying Asleep? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</measure>
    <time_frame>Baseline and 7 Days</time_frame>
    <description>Over the past 7 days patients reported &quot;Trouble staying asleep&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality: Pain Interferes With Sleep? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</measure>
    <time_frame>Baseline and 7 Days</time_frame>
    <description>Over the past 7 days patients reported &quot;Pain interferes with sleep&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality: Pain Interferes With Sleep? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</measure>
    <time_frame>Baseline and 7 Days</time_frame>
    <description>Over the past 7 days patients reported &quot;Pain interferes with sleep&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality: Wake up Feeling Tired and Worn Out? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</measure>
    <time_frame>Baseline and 7 Days</time_frame>
    <description>Over the past 7 days patients reported &quot;Wake up feeling tired and worn out&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality: Wake up Feeling Tired and Worn Out? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</measure>
    <time_frame>Baseline and 7 Days</time_frame>
    <description>Over the past 7 days patients reported &quot;Wake up feeling tired and worn out&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality: Feeling Alert During Daytime Hours? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</measure>
    <time_frame>Baseline and 7 Days</time_frame>
    <description>Over the past 7 days patients reported &quot;Feeling alert during daytime hours&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality: Feeling Alert During Daytime Hours? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</measure>
    <time_frame>Baseline and 7 Days</time_frame>
    <description>Over the past 7 days patients reported &quot;Feeling alert during daytime hours&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality: Feeling Well Rested? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</measure>
    <time_frame>Baseline and 7 Days</time_frame>
    <description>Over the past 7 days patients reported &quot;Feeling well rested&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality: Feeling Well Rested? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</measure>
    <time_frame>Baseline and 7 Days</time_frame>
    <description>Over the past 7 days patients reported &quot;Feeling well rested&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">382</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tapentadol IR First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1 if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxycodone IR First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1 if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tapentadol IR</intervention_name>
    <description>First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1, if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone IR</intervention_name>
    <description>First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1, if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy on the basis of medical history and vital signs and meeting the American
             Society of Anesthesiology (ASA) physical status I, II, or III

          -  completed screening procedures and have undergone one of the following elective
             outpatient arthroscopic surgical procedures: rotator cuff repair, labral tear repair,
             Bankart repair

          -  an arthroscopic mini-open rotator cuff repair

          -  (an arthroscopic distal clavicle resection performed in conjunction with a rotator
             cuff, labral tear or Bankart repair is also permitted)

          -  received anesthesia administered to the shoulder by interscalene nerve block

          -  receive study medication as the first oral analgesic medication following the
             orthopedic surgical procedure and expected to have moderate to severe pain requiring
             oral opioids for at least 3 days after surgery.

        Exclusion Criteria:

          -  Patients whose post-operative pain would require non opioid analgesia as standard of
             care

          -  received a non-allowed procedure

          -  received intraoperative or post-operative anesthesia and/or analgesic medications
             which are expected to provide post-operative analgesia for &gt;24 hours after discharge
             from the PACU (recovery room)

          -  received intraoperatively &gt;200 mg fentanyl or the morphine equivalent of another
             opioid (for the total procedure) or potent inhaled anesthesia (e.g., sevoflurane,
             isoflurane)

          -  received IV PCA analgesia (intravenous pump the patient controls) in the PACU or a
             PACU stay &gt;8 hours

          -  expected to require inpatient treatment in a hospital or rehabilitation unit post
             operatively

          -  anticipate any surgical procedure(s) within 7 days after the initial shoulder surgery

          -  have significant nausea and/or vomiting at the time of randomization (patients may
             receive an anti-emetic prior to or during surgery)

          -  received any of the following: long-acting or controlled-release opioids within
             1-month prior to randomization

          -  immediate release CII opioid formulations (e.g., Opana IR, Percocet, Percodan,
             oxycodone IR, Dilaudid) for &gt;5 days total within 1 month before, and within 24 hours
             of, randomization

          -  intra-articular (within a joint) or systemic steroids (except inhalers and topical
             steroids), within 1 month before randomization (exception, patients on a stable dose
             of chronic steroids for a minimum of 3 months, for a condition other than the shoulder
             pain)

          -  use of non-steroidal anti-inflammatory drugs (NSAIDs) within 24-hours of randomization

          -  have taken any CIII opioid formulation (e.g., Tylenol with Codeine) &gt;3 days/week in
             the 1-month prior to randomization

          -  treated with anticonvulsants, monoamine oxidase inhibitors (MAOIs), tricyclic
             antidepressants (TCAs), neuroleptics, or serotonin norepinephrine reuptake inhibitors
             (SNRIs) within 2 weeks before randomization

          -  positive urine drug screen (cocaine, methadone, amphetamines, cannabinoids, opiates,
             benzodiazepines, barbiturates, and oxycodone)

          -  have an active systemic or local infection

          -  significant co-existing autoimmune inflammatory conditions

          -  history of seizure disorder or epilepsy

          -  presence of any of the following: mild or moderate traumatic brain injury, stroke,
             transient ischemic attack, or brain neoplasm within 1 year of screening

          -  severe traumatic brain injury, episode(s) of unconsciousness of more than 24 hours
             duration, or post-traumatic amnesia of more than 24 hours duration within 15 years of
             screening

          -  known history of alcohol or drug abuse in the study doctor's judgment based on medical
             history

          -  known or suspected to be opioid tolerant or dependent

          -  known history of laboratory values reflecting severe kidney disease, known history of
             moderately or severely impaired liver function

          -  history of allergy to, or hypersensitivity to tapentadol, oxycodone, or other
             components of the medication

          -  history (within the past 6 months) of a major psychiatric disorder

          -  history of suicidal ideation or suicidal attempts within the past 2 years

          -  currently involved in litigation regarding their shoulder injury, have a disability
             claim or patients who are receiving Worker's Compensation due to their shoulder injury
             or are being evaluated to receive disability or Worker's Compensation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ortho-McNeil Janssen Scientific Affairs, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Ortho-McNeil Janssen Scientific Affairs, LLC</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2008</study_first_submitted>
  <study_first_submitted_qc>December 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2008</study_first_posted>
  <results_first_submitted>March 10, 2011</results_first_submitted>
  <results_first_submitted_qc>December 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 10, 2012</results_first_posted>
  <last_update_submitted>November 13, 2012</last_update_submitted>
  <last_update_submitted_qc>November 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>analgesia</keyword>
  <keyword>postoperative pain</keyword>
  <keyword>opioid</keyword>
  <keyword>rotator cuff repair</keyword>
  <keyword>labral tear repair</keyword>
  <keyword>Bankart procedure</keyword>
  <keyword>oxycodone</keyword>
  <keyword>tapentadol</keyword>
  <keyword>arthroscopic shoulder surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period for this outpatient, multicenter US only study occurred between Jan. 14, 2009 and Mar. 19, 2010</recruitment_details>
      <pre_assignment_details>The study consisted of a screening period (up to 21 days) and a double-blind active treatment period (7 days, but can be up to 9 days).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tapentadol IR</title>
          <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
        </group>
        <group group_id="P2">
          <title>Oxycodone IR</title>
          <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
                <participants group_id="P2" count="188"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Take Drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tapentadol IR</title>
          <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
        </group>
        <group group_id="B2">
          <title>Oxycodone IR</title>
          <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="192"/>
            <count group_id="B2" value="186"/>
            <count group_id="B3" value="378"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>The summary statistics provided for baseline characteristic was based on safety population that includes 192 subjects in tapentadol group and 186 subjects in oxycodone group. The safety population includes randomized subjects took at least one dose of study drug.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>The summary statistics provided for baseline characteristic was based on safety population that includes 192 subjects in tapentadol group and 186 subjects in oxycodone group. The safety population includes randomized subjects took at least one dose of study drug.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.2" spread="14.98"/>
                    <measurement group_id="B2" value="52.7" spread="14.97"/>
                    <measurement group_id="B3" value="52.9" spread="14.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>The summary statistics provided for baseline characteristic was based on safety population that includes 192 subjects in tapentadol group and 186 subjects in oxycodone group. The safety population includes randomized subjects took at least one dose of study drug.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>The summary statistics provided for baseline characteristic was based on safety population that includes 192 subjects in tapentadol group and 186 subjects in oxycodone group. The safety population includes randomized subjects took at least one dose of study drug.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>USA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 3 Days (72 Hours)</title>
        <description>Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID72 was calculated as the time-weighted Sum of PID scores over 72 hours. The range of SPID72 is from -720 to 720. The higher value in SPID indicates greater pain relief.</description>
        <time_frame>3 Days (72 hours)</time_frame>
        <population>The modified Intent-to-Treat(mITT) population was defined as all randomized subjects who took at least one dose of study drug within 24 hours of randomization and had a baseline pain intensity score &gt;= 4 on an 11-point numeric rating scale (NRS).</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 3 Days (72 Hours)</title>
          <description>Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID72 was calculated as the time-weighted Sum of PID scores over 72 hours. The range of SPID72 is from -720 to 720. The higher value in SPID indicates greater pain relief.</description>
          <population>The modified Intent-to-Treat(mITT) population was defined as all randomized subjects who took at least one dose of study drug within 24 hours of randomization and had a baseline pain intensity score &gt;= 4 on an 11-point numeric rating scale (NRS).</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" spread="134.18"/>
                    <measurement group_id="O2" value="40.5" spread="155.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tapentadol IR versus Oxycodone IR</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Primary hypothesis test for non-inferiority of tapentadol IR over oxycodone IR required that upper limit of 95% CI for LS mean difference (oxycodone IR minus tapentadol IR) was less than the inferiority margin (&lt; 72). If the upper limit was less than 0 then tapentadol IR was superior to oxycodone IR for SPID over 3 days at a 5% level of significance.</non_inferiority_desc>
            <p_value>0.5265</p_value>
            <p_value_desc>Analysis of covariance (ANCOVA) model included baseline pain intensity score as the covariate and treatment and pooled center as class variables.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least square mean difference</param_type>
            <param_value>9.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.9</ci_lower_limit>
            <ci_upper_limit>36.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Kaplan-Meier Estimates for Time to Achieve 50% Reduction in Pain Intensity From Baseline</title>
        <description>From date of first administration of study medication to time to achieve adequate 50% reduction in pain intensity from baseline score. Censored observations included subjects who completed or discontinued from the study without a 50% reduction in pain intensity from baseline score. If a subject discontinued due to lack of efficacy (including rescue medication), the subject was censored on Day 7, 12 PM.</description>
        <time_frame>7 Days</time_frame>
        <population>Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Kaplan-Meier Estimates for Time to Achieve 50% Reduction in Pain Intensity From Baseline</title>
          <description>From date of first administration of study medication to time to achieve adequate 50% reduction in pain intensity from baseline score. Censored observations included subjects who completed or discontinued from the study without a 50% reduction in pain intensity from baseline score. If a subject discontinued due to lack of efficacy (including rescue medication), the subject was censored on Day 7, 12 PM.</description>
          <population>Modified Intent-to-Treat Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.3" lower_limit="100.3">NA: Not Applicable, as not enough participants achieved 50% pain reduction and upper limit of confidence interval.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="99.9">NA: Not Applicable, as not enough participants achieved 50% pain reduction and upper limit of confidence interval.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7306</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Kaplan-Meier Estimates for Time to Achieve 30% Reduction in Pain Intensity From Baseline</title>
        <description>From date of first administration of study medication to time to achieve adequate 30% reduction in pain intensity from baseline score. Censored observations included subjects who completed or discontinued from the study without a 30% reduction in pain intensity from baseline score. If a subject discontinued due to lack of efficacy (including rescue medication), the subject was censored on Day 7, 12 PM.</description>
        <time_frame>7 Days</time_frame>
        <population>Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Kaplan-Meier Estimates for Time to Achieve 30% Reduction in Pain Intensity From Baseline</title>
          <description>From date of first administration of study medication to time to achieve adequate 30% reduction in pain intensity from baseline score. Censored observations included subjects who completed or discontinued from the study without a 30% reduction in pain intensity from baseline score. If a subject discontinued due to lack of efficacy (including rescue medication), the subject was censored on Day 7, 12 PM.</description>
          <population>Modified Intent-to-Treat Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" lower_limit="54.5" upper_limit="89.0"/>
                    <measurement group_id="O2" value="66.4" lower_limit="46.0" upper_limit="134.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8524</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of 30% Responder Rate (With Imputation) on Day 3</title>
        <description>The 30% responder rate was defined as the proportion of participants with a value of percentage change greater than or equal to the 30% from baseline in pain intensity at Day 3 (average of Day 3 PM and Day 4 AM). If a subject has only the Day 3 PM value or Day 4 AM value, then response rate will be based on the non-missing value. If a subject withdraws or uses rescue medication before Day 3 PM then Baseline Observation Carried Forward (BOCF) will be imputed. Last Observation Carried Forward (LOCF) may be used if no value afterward.</description>
        <time_frame>Day 3</time_frame>
        <population>Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of 30% Responder Rate (With Imputation) on Day 3</title>
          <description>The 30% responder rate was defined as the proportion of participants with a value of percentage change greater than or equal to the 30% from baseline in pain intensity at Day 3 (average of Day 3 PM and Day 4 AM). If a subject has only the Day 3 PM value or Day 4 AM value, then response rate will be based on the non-missing value. If a subject withdraws or uses rescue medication before Day 3 PM then Baseline Observation Carried Forward (BOCF) will be imputed. Last Observation Carried Forward (LOCF) may be used if no value afterward.</description>
          <population>Modified Intent-to-Treat Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5"/>
                    <measurement group_id="O2" value="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9078</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel test (Row Mean Score option) controlling for pooled investigator centers.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of 30% Responder Rate (With Imputation) on Day 7</title>
        <description>The 30% responder rate was defined as the proportion of participants with a value of percentage change greater than or equal to the 30% from baseline in pain intensity at Day 7 (average of Day 6 PM and Day 7 AM). If a subject has only the Day 6 PM value or Day 7 AM value, then response rate will be based on the non-missing value. If a subject withdraws or uses rescue medication before Day 6 PM then BOCF will be imputed. LOCF may be used if no value afterward.</description>
        <time_frame>Day 7</time_frame>
        <population>Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of 30% Responder Rate (With Imputation) on Day 7</title>
          <description>The 30% responder rate was defined as the proportion of participants with a value of percentage change greater than or equal to the 30% from baseline in pain intensity at Day 7 (average of Day 6 PM and Day 7 AM). If a subject has only the Day 6 PM value or Day 7 AM value, then response rate will be based on the non-missing value. If a subject withdraws or uses rescue medication before Day 6 PM then BOCF will be imputed. LOCF may be used if no value afterward.</description>
          <population>Modified Intent-to-Treat Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1"/>
                    <measurement group_id="O2" value="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2633</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel test (Row Mean Score option) controlling for pooled investigator centers.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of 50% Responder Rate (With Imputation) on Day 3</title>
        <description>The 50% responder rate was defined as the proportion of participants with a value of percentage change greater than or equal to the 50% from baseline in pain intensity at Day 3 (average of Day 3 PM and Day 4 AM). If a subject has only the Day 3 PM value or Day 4 AM value, then response rate will be based on the non-missing value. If a subject withdraws or uses rescue medication before Day 3 PM then BOCF will be imputed. LOCF may be used if no value afterward.</description>
        <time_frame>Day 3</time_frame>
        <population>Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of 50% Responder Rate (With Imputation) on Day 3</title>
          <description>The 50% responder rate was defined as the proportion of participants with a value of percentage change greater than or equal to the 50% from baseline in pain intensity at Day 3 (average of Day 3 PM and Day 4 AM). If a subject has only the Day 3 PM value or Day 4 AM value, then response rate will be based on the non-missing value. If a subject withdraws or uses rescue medication before Day 3 PM then BOCF will be imputed. LOCF may be used if no value afterward.</description>
          <population>Modified Intent-to-Treat Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4498</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel test (Row Mean Score option) controlling for pooled investigator centers.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of 50% Responder Rate (With Imputation) on Day 7</title>
        <description>The 50% responder rate was defined as the proportion of participants with a value of percentage change greater than or equal to the 50% from baseline in pain intensity at Day 7 (average of Day 6 PM and Day 7 AM). If a subject has only the Day 6 PM value or Day 7 AM value, then response rate will be based on the non-missing value. If a subject withdraws or uses rescue medication before Day 6 PM then BOCF will be imputed. LOCF may be used if no value afterward.</description>
        <time_frame>Day 7</time_frame>
        <population>Modified Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of 50% Responder Rate (With Imputation) on Day 7</title>
          <description>The 50% responder rate was defined as the proportion of participants with a value of percentage change greater than or equal to the 50% from baseline in pain intensity at Day 7 (average of Day 6 PM and Day 7 AM). If a subject has only the Day 6 PM value or Day 7 AM value, then response rate will be based on the non-missing value. If a subject withdraws or uses rescue medication before Day 6 PM then BOCF will be imputed. LOCF may be used if no value afterward.</description>
          <population>Modified Intent-to-Treat Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4"/>
                    <measurement group_id="O2" value="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2158</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel test (Row Mean Score option) controlling for pooled investigator centers.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 2 Days (48 Hours)</title>
        <description>Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID48 was calculated as the time-weighted Sum of PID scores over 48 hours. The range of SPID48 is from -480 to 480. The higher value in SPID indicates greater pain relief.</description>
        <time_frame>2 Days (48 hours)</time_frame>
        <population>The modified Intent-to-Treat(mITT) population was defined as all randomized subjects who took at least one dose of study drug within 24 hours of randomization and had a baseline pain intensity score &gt;= 4 on an 11-point numeric rating scale (NRS).</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 2 Days (48 Hours)</title>
          <description>Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID48 was calculated as the time-weighted Sum of PID scores over 48 hours. The range of SPID48 is from -480 to 480. The higher value in SPID indicates greater pain relief.</description>
          <population>The modified Intent-to-Treat(mITT) population was defined as all randomized subjects who took at least one dose of study drug within 24 hours of randomization and had a baseline pain intensity score &gt;= 4 on an 11-point numeric rating scale (NRS).</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="88.05"/>
                    <measurement group_id="O2" value="14.6" spread="102.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4811</p_value>
            <p_value_desc>Analysis of covariance (ANCOVA) model included baseline pain intensity score as the covariate and treatment and pooled center as class variables.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least square mean difference</param_type>
            <param_value>6.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.8</ci_lower_limit>
            <ci_upper_limit>25.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 7 Days</title>
        <description>Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID over 7 Days was calculated as the time-weighted Sum of PID scores up to Day 7, 8 AM. The range is from -1440 to 1440. The higher value in SPID indicates greater pain relief.</description>
        <time_frame>7 Days</time_frame>
        <population>The modified Intent-to-Treat(mITT) population was defined as all randomized subjects who took at least one dose of study drug within 24 hours of randomization and had a baseline pain intensity score &gt;= 4 on an 11-point numeric rating scale (NRS).</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 7 Days</title>
          <description>Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID over 7 Days was calculated as the time-weighted Sum of PID scores up to Day 7, 8 AM. The range is from -1440 to 1440. The higher value in SPID indicates greater pain relief.</description>
          <population>The modified Intent-to-Treat(mITT) population was defined as all randomized subjects who took at least one dose of study drug within 24 hours of randomization and had a baseline pain intensity score &gt;= 4 on an 11-point numeric rating scale (NRS).</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.1" spread="277.20"/>
                    <measurement group_id="O2" value="122.1" spread="299.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7405</p_value>
            <p_value_desc>Analysis of covariance (ANCOVA) model included baseline pain intensity score as the covariate and treatment and pooled center as class variables.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-9.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>28.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.7</ci_lower_limit>
            <ci_upper_limit>46.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary and Analysis of Total Pain Relief (TOTPAR) (With Imputation) Over 2 Days (48 Hours)</title>
        <description>Pain Relief was defined as a 5-point categorical scale of 0-4 (0=none, 1=A little, 2=Some, 3=A lot, 4=Complete). Total Pain Relief (TOTPAR) was calculated as the time-weighted sum over all pain relief up to hour 48. The range of TOTPAR over 2 days is from 0 to 192. A higher value in TOTPAR indicated greater pain relief.</description>
        <time_frame>2 Days (48 hours)</time_frame>
        <population>The modified Intent-to-Treat(mITT) population was defined as all randomized subjects who took at least one dose of study drug within 24 hours of randomization and had a baseline pain intensity score &gt;= 4 on an 11-point numeric rating scale (NRS).</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Summary and Analysis of Total Pain Relief (TOTPAR) (With Imputation) Over 2 Days (48 Hours)</title>
          <description>Pain Relief was defined as a 5-point categorical scale of 0-4 (0=none, 1=A little, 2=Some, 3=A lot, 4=Complete). Total Pain Relief (TOTPAR) was calculated as the time-weighted sum over all pain relief up to hour 48. The range of TOTPAR over 2 days is from 0 to 192. A higher value in TOTPAR indicated greater pain relief.</description>
          <population>The modified Intent-to-Treat(mITT) population was defined as all randomized subjects who took at least one dose of study drug within 24 hours of randomization and had a baseline pain intensity score &gt;= 4 on an 11-point numeric rating scale (NRS).</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" spread="48.13"/>
                    <measurement group_id="O2" value="92.0" spread="50.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3097</p_value>
            <p_value_desc>Analysis of covariance (ANCOVA) model included baseline pain intensity score as the covariate and treatment and pooled center as class variables.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-5.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.5</ci_lower_limit>
            <ci_upper_limit>5.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary and Analysis of Total Pain Relief (TOTPAR) (With Imputation) Over 3 Days (72hours)</title>
        <description>Pain Relief was defined as a 5-point categorical scale of 0-4 (0=none, 1=A little, 2=Some, 3=A lot, 4=Complete). Total Pain Relief (TOTPAR) was calculated as the time-weighted sum over all pain relief up to hour 72. The range of TOTPAR over 3 days is from 0 to 288. A higher value in TOTPAR indicated greater pain relief.</description>
        <time_frame>3 Days (72hours)</time_frame>
        <population>The modified Intent-to-Treat(mITT) population was defined as all randomized subjects who took at least one dose of study drug within 24 hours of randomization and had a baseline pain intensity score &gt;= 4 on an 11-point numeric rating scale (NRS).</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Summary and Analysis of Total Pain Relief (TOTPAR) (With Imputation) Over 3 Days (72hours)</title>
          <description>Pain Relief was defined as a 5-point categorical scale of 0-4 (0=none, 1=A little, 2=Some, 3=A lot, 4=Complete). Total Pain Relief (TOTPAR) was calculated as the time-weighted sum over all pain relief up to hour 72. The range of TOTPAR over 3 days is from 0 to 288. A higher value in TOTPAR indicated greater pain relief.</description>
          <population>The modified Intent-to-Treat(mITT) population was defined as all randomized subjects who took at least one dose of study drug within 24 hours of randomization and had a baseline pain intensity score &gt;= 4 on an 11-point numeric rating scale (NRS).</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.3" spread="71.9"/>
                    <measurement group_id="O2" value="140.9" spread="77.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2179</p_value>
            <p_value_desc>Analysis of covariance (ANCOVA) model included baseline pain intensity score as the covariate and treatment and pooled center as class variables.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-10.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.7</ci_lower_limit>
            <ci_upper_limit>6.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary and Analysis of Total Pain Relief (TOTPAR) (With Imputation) Over 7 Days</title>
        <description>Pain Relief was defined as a 5-point categorical scale of 0-4 (0=none, 1=A little, 2=Some, 3=A lot, 4=Complete). Total Pain Relief (TOTPAR) was calculated as the time-weighted sum over all pain relief up to Day 7, 8 AM. The range of TOTPAR over 7 days is from 0 to 576. A higher value in TOTPAR indicated greater pain relief.</description>
        <time_frame>7 Days</time_frame>
        <population>The modified Intent-to-Treat(mITT) population was defined as all randomized subjects who took at least one dose of study drug within 24 hours of randomization and had a baseline pain intensity score &gt;= 4 on an 11-point numeric rating scale (NRS).</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Summary and Analysis of Total Pain Relief (TOTPAR) (With Imputation) Over 7 Days</title>
          <description>Pain Relief was defined as a 5-point categorical scale of 0-4 (0=none, 1=A little, 2=Some, 3=A lot, 4=Complete). Total Pain Relief (TOTPAR) was calculated as the time-weighted sum over all pain relief up to Day 7, 8 AM. The range of TOTPAR over 7 days is from 0 to 576. A higher value in TOTPAR indicated greater pain relief.</description>
          <population>The modified Intent-to-Treat(mITT) population was defined as all randomized subjects who took at least one dose of study drug within 24 hours of randomization and had a baseline pain intensity score &gt;= 4 on an 11-point numeric rating scale (NRS).</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299.1" spread="137.33"/>
                    <measurement group_id="O2" value="272.9" spread="154.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1051</p_value>
            <p_value_desc>Analysis of covariance (ANCOVA) model included baseline pain intensity score as the covariate and treatment and pooled center as class variables.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-26.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>16.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.1</ci_lower_limit>
            <ci_upper_limit>5.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary and Analysis of the Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) (With Imputation) Over 2 Days (48 Hours)</title>
        <description>The Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) was derived from Sum of TOTPAR and SPID. The range of SPRID over 2 days is from -480 to 672. A higher value in SPRID indicated greater pain relief.</description>
        <time_frame>2 Days (48 hours)</time_frame>
        <population>The modified Intent-to-Treat(mITT) population was defined as all randomized subjects who took at least one dose of study drug within 24 hours of randomization and had a baseline pain intensity score &gt;= 4 on an 11-point numeric rating scale (NRS).</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Summary and Analysis of the Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) (With Imputation) Over 2 Days (48 Hours)</title>
          <description>The Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) was derived from Sum of TOTPAR and SPID. The range of SPRID over 2 days is from -480 to 672. A higher value in SPRID indicated greater pain relief.</description>
          <population>The modified Intent-to-Treat(mITT) population was defined as all randomized subjects who took at least one dose of study drug within 24 hours of randomization and had a baseline pain intensity score &gt;= 4 on an 11-point numeric rating scale (NRS).</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.2" spread="109.89"/>
                    <measurement group_id="O2" value="106.6" spread="125.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9367</p_value>
            <p_value_desc>Analysis of covariance (ANCOVA) model included baseline pain intensity score as the covariate and treatment and pooled center as class variables.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least square mean difference</param_type>
            <param_value>1.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.8</ci_lower_limit>
            <ci_upper_limit>24.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary and Analysis of the Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) (With Imputation) Over 3 Days (72 Hours)</title>
        <description>The Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) was derived from Sum of TOTPAR and SPID. The range of SPRID over 3 days is from -720 to 1008. A higher value in SPRID indicated greater pain relief.</description>
        <time_frame>3 Days (72hours)</time_frame>
        <population>The modified Intent-to-Treat(mITT) population was defined as all randomized subjects who took at least one dose of study drug within 24 hours of randomization and had a baseline pain intensity score &gt;= 4 on an 11-point numeric rating scale (NRS).</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Summary and Analysis of the Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) (With Imputation) Over 3 Days (72 Hours)</title>
          <description>The Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) was derived from Sum of TOTPAR and SPID. The range of SPRID over 3 days is from -720 to 1008. A higher value in SPRID indicated greater pain relief.</description>
          <population>The modified Intent-to-Treat(mITT) population was defined as all randomized subjects who took at least one dose of study drug within 24 hours of randomization and had a baseline pain intensity score &gt;= 4 on an 11-point numeric rating scale (NRS).</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186.1" spread="168.64"/>
                    <measurement group_id="O2" value="181.4" spread="193.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9441</p_value>
            <p_value_desc>Analysis of covariance (ANCOVA) model included baseline pain intensity score as the covariate and treatment and pooled center as class variables.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>18.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.8</ci_lower_limit>
            <ci_upper_limit>35.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary and Analysis of the Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) (With Imputation) Over 7 Days</title>
        <description>The Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) was derived from Sum of TOTPAR and SPID. The range of SPRID over 7 days is from -1440 to 2016. A higher value in SPRID indicated greater pain relief.</description>
        <time_frame>7 Days</time_frame>
        <population>The modified Intent-to-Treat(mITT) population was defined as all randomized subjects who took at least one dose of study drug within 24 hours of randomization and had a baseline pain intensity score &gt;= 4 on an 11-point numeric rating scale (NRS).</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Summary and Analysis of the Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) (With Imputation) Over 7 Days</title>
          <description>The Sum of Total Pain Relief and Sum of Pain Intensity Difference (SPRID) was derived from Sum of TOTPAR and SPID. The range of SPRID over 7 days is from -1440 to 2016. A higher value in SPRID indicated greater pain relief.</description>
          <population>The modified Intent-to-Treat(mITT) population was defined as all randomized subjects who took at least one dose of study drug within 24 hours of randomization and had a baseline pain intensity score &gt;= 4 on an 11-point numeric rating scale (NRS).</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="435.2" spread="354.59"/>
                    <measurement group_id="O2" value="395.0" spread="386.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3427</p_value>
            <p_value_desc>Analysis of covariance (ANCOVA) model included baseline pain intensity score as the covariate and treatment and pooled center as class variables.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-35.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>37.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-109.3</ci_lower_limit>
            <ci_upper_limit>38.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Satisfaction With Treatment</title>
        <description>Treatment satisfaction was measured using a 7-point scale where 1 = very satisfied and 7 = very dissatisfied</description>
        <time_frame>7 Days</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Satisfaction With Treatment</title>
          <description>Treatment satisfaction was measured using a 7-point scale where 1 = very satisfied and 7 = very dissatisfied</description>
          <population>Intent-to-Treat Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3"/>
                    <measurement group_id="O2" value="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6"/>
                    <measurement group_id="O2" value="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither satisfied nor dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9"/>
                    <measurement group_id="O2" value="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1618</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel test (row mean score option) controlling for pooled investigator centers.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Change (PGIC) at End of Study</title>
        <description>Patient Global Impression of Change (PGIC) was defined as the 7-point numeric scale, where 1=very much improved to 7=very much worse.</description>
        <time_frame>7 Days</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Change (PGIC) at End of Study</title>
          <description>Patient Global Impression of Change (PGIC) was defined as the 7-point numeric scale, where 1=very much improved to 7=very much worse.</description>
          <population>Intent-to-Treat Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6"/>
                    <measurement group_id="O2" value="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9"/>
                    <measurement group_id="O2" value="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0481</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel test (row mean score option) controlling for pooled investigator centers.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinician Global Impression of Change (CGIC) at End of Study</title>
        <description>Clinician Global Impression of Change (CGIC) was defined as the 7-point numeric scale, where 1=very much improved to 7=very much worse.</description>
        <time_frame>7 Days</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician Global Impression of Change (CGIC) at End of Study</title>
          <description>Clinician Global Impression of Change (CGIC) was defined as the 7-point numeric scale, where 1=very much improved to 7=very much worse.</description>
          <population>Intent-to-Treat Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4"/>
                    <measurement group_id="O2" value="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0109</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel test (row mean score option) controlling for pooled investigator centers</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Medical Resource Utilization ‚Äì Number of Calls by the Subject to Study Site Personnel</title>
        <description>Information associated with contacts with a healthcare professional was collected by the investigator and study staff for all subjects throughout the study.</description>
        <time_frame>7 Days</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Medical Resource Utilization ‚Äì Number of Calls by the Subject to Study Site Personnel</title>
          <description>Information associated with contacts with a healthcare professional was collected by the investigator and study staff for all subjects throughout the study.</description>
          <population>Intent-to-Treat Population</population>
          <units>Number of calls</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total number of subjects who made calls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of adverse event related calls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of pain-related calls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of non-medical/administrative calls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of other medical conditions calls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total number of calls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Medical Resource Utilization ‚Äì Number of Other Types of Contacts With Healthcare Professionals</title>
        <description>Information associated with contacts with a healthcare professional was collected by the investigator and study staff for all subjects throughout the study.</description>
        <time_frame>7 Days</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol IR</title>
            <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone IR</title>
            <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Medical Resource Utilization ‚Äì Number of Other Types of Contacts With Healthcare Professionals</title>
          <description>Information associated with contacts with a healthcare professional was collected by the investigator and study staff for all subjects throughout the study.</description>
          <population>Intent-to-Treat Population</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients visited a healthcare professional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patient with scheduled visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patient with unscheduled visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patient with Internist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patient with Orthopedic surgeon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patient with Physical therapist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patient with Primary care physician</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient with other healthcare professional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patient with emergency room visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patient with hospital admissions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality: Trouble Falling Asleep? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</title>
        <description>Over the past 7 days patients reported &quot;trouble falling asleep&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
        <time_frame>Baseline and 7 Days</time_frame>
        <population>Tapentadol IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
        <group_list>
          <group group_id="O1">
            <title>End of Study: Not at All</title>
            <description>Tapentadol IR participants who chose category of 'Not at all' for the measurement at the end of study.</description>
          </group>
          <group group_id="O2">
            <title>End of Study: 1-2 Days</title>
            <description>Tapentadol IR participants who chose category of '1-2 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O3">
            <title>End of Study: 3-5 Days</title>
            <description>Tapentadol IR participants who chose category of '3-5 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O4">
            <title>End of Study: 6-7 Days</title>
            <description>Tapentadol IR participants who chose category of '6-7 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O5">
            <title>Baseline - Total</title>
            <description>Total Tapentadol IR participants at the baseline.</description>
          </group>
          <group group_id="O6">
            <title>End of Study: Missing the Measurement</title>
            <description>Tapentadol IR Participants who missed the measurement at the end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality: Trouble Falling Asleep? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</title>
          <description>Over the past 7 days patients reported &quot;trouble falling asleep&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
          <population>Tapentadol IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="104"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1-2 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="40"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 3-5 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 6-7 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Miss the measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality: Trouble Falling Asleep? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</title>
        <description>Over the past 7 days patients reported &quot;trouble falling asleep&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
        <time_frame>Baseline and 7 Days</time_frame>
        <population>Oxycodone IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
        <group_list>
          <group group_id="O1">
            <title>End of Study: Not at All</title>
            <description>Oxycodone IR participants who chose category of 'Not at all' for the measurement at the end of study.</description>
          </group>
          <group group_id="O2">
            <title>End of Study: 1-2 Days</title>
            <description>Oxycodone IR participants who chose category of '1-2 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O3">
            <title>End of Study: 3-5 Days</title>
            <description>Oxycodone IR participants who chose category of '3-5 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O4">
            <title>End of Study: 6-7 Days</title>
            <description>Oxycodone IR participants who chose category of '6-7 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O5">
            <title>Baseline - Total</title>
            <description>Total Oxycodone IR participants at the baseline.</description>
          </group>
          <group group_id="O6">
            <title>End of Study: Missing the Measurement</title>
            <description>Oxycodone IR Participants who missed the measurement at the end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality: Trouble Falling Asleep? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</title>
          <description>Over the past 7 days patients reported &quot;trouble falling asleep&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
          <population>Oxycodone IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="181"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="105"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1-2 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 3-5 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 6-7 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Miss the measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality: Wake up Several Times During Night? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</title>
        <description>Over the past 7 days patients reported &quot;Wake up several times during night&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
        <time_frame>Baseline and 7 Days</time_frame>
        <population>Tapentadol IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
        <group_list>
          <group group_id="O1">
            <title>End of Study: Not at All</title>
            <description>Tapentadol IR participants who chose category of 'Not at all' for the measurement at the end of study.</description>
          </group>
          <group group_id="O2">
            <title>End of Study: 1-2 Days</title>
            <description>Tapentadol IR participants who chose category of '1-2 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O3">
            <title>End of Study: 3-5 Days</title>
            <description>Tapentadol IR participants who chose category of '3-5 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O4">
            <title>End of Study: 6-7 Days</title>
            <description>Tapentadol IR participants who chose category of '6-7 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O5">
            <title>Baseline - Total</title>
            <description>Total Tapentadol IR participants at the baseline.</description>
          </group>
          <group group_id="O6">
            <title>End of Study: Missing the Measurement</title>
            <description>Tapentadol IR Participants who missed the measurement at the end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality: Wake up Several Times During Night? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</title>
          <description>Over the past 7 days patients reported &quot;Wake up several times during night&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
          <population>Tapentadol IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1-2 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 3-5 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="53"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 6-7 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="61"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Miss the measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality: Wake up Several Times During Night? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</title>
        <description>Over the past 7 days patients reported &quot;Wake up several times during night&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
        <time_frame>Baseline and 7 Days</time_frame>
        <population>Oxycodone IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
        <group_list>
          <group group_id="O1">
            <title>End of Study: Not at All</title>
            <description>Oxycodone IR participants who chose category of 'Not at all' for the measurement at the end of study.</description>
          </group>
          <group group_id="O2">
            <title>End of Study: 1-2 Days</title>
            <description>Oxycodone IR participants who chose category of '1-2 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O3">
            <title>End of Study: 3-5 Days</title>
            <description>Oxycodone IR participants who chose category of '3-5 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O4">
            <title>End of Study: 6-7 Days</title>
            <description>Oxycodone IR participants who chose category of '6-7 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O5">
            <title>Baseline - Total</title>
            <description>Total Oxycodone IR participants at the baseline.</description>
          </group>
          <group group_id="O6">
            <title>End of Study: Missing the Measurement</title>
            <description>Oxycodone IR Participants who missed the measurement at the end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality: Wake up Several Times During Night? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</title>
          <description>Over the past 7 days patients reported &quot;Wake up several times during night&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
          <population>Oxycodone IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="181"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="44"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1-2 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="46"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 3-5 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 6-7 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="53"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Miss the measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality: Trouble Staying Asleep? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</title>
        <description>Over the past 7 days patients reported &quot;Trouble staying asleep&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
        <time_frame>Baseline and 7 Days</time_frame>
        <population>Tapentadol IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
        <group_list>
          <group group_id="O1">
            <title>End of Study: Not at All</title>
            <description>Tapentadol IR participants who chose category of 'Not at all' for the measurement at the end of study.</description>
          </group>
          <group group_id="O2">
            <title>End of Study: 1-2 Days</title>
            <description>Tapentadol IR participants who chose category of '1-2 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O3">
            <title>End of Study: 3-5 Days</title>
            <description>Tapentadol IR participants who chose category of '3-5 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O4">
            <title>End of Study: 6-7 Days</title>
            <description>Tapentadol IR participants who chose category of '6-7 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O5">
            <title>Baseline - Total</title>
            <description>Total Tapentadol IR participants at the baseline.</description>
          </group>
          <group group_id="O6">
            <title>End of Study: Missing the Measurement</title>
            <description>Tapentadol IR Participants who missed the measurement at the end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality: Trouble Staying Asleep? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</title>
          <description>Over the past 7 days patients reported &quot;Trouble staying asleep&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
          <population>Tapentadol IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="81"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1-2 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="41"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 3-5 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 6-7 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Miss the measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality: Trouble Staying Asleep? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</title>
        <description>Over the past 7 days patients reported &quot;Trouble staying asleep&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
        <time_frame>Baseline and 7 Days</time_frame>
        <population>Oxycodone IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
        <group_list>
          <group group_id="O1">
            <title>End of Study: Not at All</title>
            <description>Oxycodone IR participants who chose category of 'Not at all' for the measurement at the end of study.</description>
          </group>
          <group group_id="O2">
            <title>End of Study: 1-2 Days</title>
            <description>Oxycodone IR participants who chose category of '1-2 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O3">
            <title>End of Study: 3-5 Days</title>
            <description>Oxycodone IR participants who chose category of '3-5 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O4">
            <title>End of Study: 6-7 Days</title>
            <description>Oxycodone IR participants who chose category of '6-7 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O5">
            <title>Baseline - Total</title>
            <description>Total Oxycodone IR participants at the baseline.</description>
          </group>
          <group group_id="O6">
            <title>End of Study: Missing the Measurement</title>
            <description>Oxycodone IR Participants who missed the measurement at the end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality: Trouble Staying Asleep? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</title>
          <description>Over the past 7 days patients reported &quot;Trouble staying asleep&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
          <population>Oxycodone IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="181"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="77"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1-2 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 3-5 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 6-7 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Miss the measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality: Pain Interferes With Sleep? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</title>
        <description>Over the past 7 days patients reported &quot;Pain interferes with sleep&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
        <time_frame>Baseline and 7 Days</time_frame>
        <population>Tapentadol IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
        <group_list>
          <group group_id="O1">
            <title>End of Study: Not at All</title>
            <description>Tapentadol IR participants who chose category of 'Not at all' for the measurement at the end of study.</description>
          </group>
          <group group_id="O2">
            <title>End of Study: 1-2 Days</title>
            <description>Tapentadol IR participants who chose category of '1-2 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O3">
            <title>End of Study: 3-5 Days</title>
            <description>Tapentadol IR participants who chose category of '3-5 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O4">
            <title>End of Study: 6-7 Days</title>
            <description>Tapentadol IR participants who chose category of '6-7 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O5">
            <title>Baseline - Total</title>
            <description>Total Tapentadol IR participants at the baseline.</description>
          </group>
          <group group_id="O6">
            <title>End of Study: Missing the Measurement</title>
            <description>Tapentadol IR Participants who missed the measurement at the end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality: Pain Interferes With Sleep? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</title>
          <description>Over the past 7 days patients reported &quot;Pain interferes with sleep&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
          <population>Tapentadol IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="56"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1-2 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="46"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 3-5 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 6-7 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="51"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Miss the measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality: Pain Interferes With Sleep? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</title>
        <description>Over the past 7 days patients reported &quot;Pain interferes with sleep&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
        <time_frame>Baseline and 7 Days</time_frame>
        <population>Oxycodone IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
        <group_list>
          <group group_id="O1">
            <title>End of Study: Not at All</title>
            <description>Oxycodone IR participants who chose category of 'Not at all' for the measurement at the end of study.</description>
          </group>
          <group group_id="O2">
            <title>End of Study: 1-2 Days</title>
            <description>Oxycodone IR participants who chose category of '1-2 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O3">
            <title>End of Study: 3-5 Days</title>
            <description>Oxycodone IR participants who chose category of '3-5 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O4">
            <title>End of Study: 6-7 Days</title>
            <description>Oxycodone IR participants who chose category of '6-7 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O5">
            <title>Baseline - Total</title>
            <description>Total Oxycodone IR participants at the baseline.</description>
          </group>
          <group group_id="O6">
            <title>End of Study: Missing the Measurement</title>
            <description>Oxycodone IR Participants who missed the measurement at the end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality: Pain Interferes With Sleep? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</title>
          <description>Over the past 7 days patients reported &quot;Pain interferes with sleep&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
          <population>Oxycodone IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="181"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="57"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1-2 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 3-5 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 6-7 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="54"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Miss the measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality: Wake up Feeling Tired and Worn Out? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</title>
        <description>Over the past 7 days patients reported &quot;Wake up feeling tired and worn out&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
        <time_frame>Baseline and 7 Days</time_frame>
        <population>Tapentadol IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
        <group_list>
          <group group_id="O1">
            <title>End of Study: Not at All</title>
            <description>Tapentadol IR participants who chose category of 'Not at all' for the measurement at the end of study.</description>
          </group>
          <group group_id="O2">
            <title>End of Study: 1-2 Days</title>
            <description>Tapentadol IR participants who chose category of '1-2 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O3">
            <title>End of Study: 3-5 Days</title>
            <description>Tapentadol IR participants who chose category of '3-5 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O4">
            <title>End of Study: 6-7 Days</title>
            <description>Tapentadol IR participants who chose category of '6-7 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O5">
            <title>Baseline - Total</title>
            <description>Total Tapentadol IR participants at the baseline.</description>
          </group>
          <group group_id="O6">
            <title>End of Study: Missing the Measurement</title>
            <description>Tapentadol IR Participants who missed the measurement at the end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality: Wake up Feeling Tired and Worn Out? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</title>
          <description>Over the past 7 days patients reported &quot;Wake up feeling tired and worn out&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
          <population>Tapentadol IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="71"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1-2 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="49"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 3-5 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 6-7 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Miss the measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality: Wake up Feeling Tired and Worn Out? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</title>
        <description>Over the past 7 days patients reported &quot;Wake up feeling tired and worn out&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
        <time_frame>Baseline and 7 Days</time_frame>
        <population>Oxycodone IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
        <group_list>
          <group group_id="O1">
            <title>End of Study: Not at All</title>
            <description>Oxycodone IR participants who chose category of 'Not at all' for the measurement at the end of study.</description>
          </group>
          <group group_id="O2">
            <title>End of Study: 1-2 Days</title>
            <description>Oxycodone IR participants who chose category of '1-2 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O3">
            <title>End of Study: 3-5 Days</title>
            <description>Oxycodone IR participants who chose category of '3-5 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O4">
            <title>End of Study: 6-7 Days</title>
            <description>Oxycodone IR participants who chose category of '6-7 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O5">
            <title>Baseline - Total</title>
            <description>Total Oxycodone IR participants at the baseline.</description>
          </group>
          <group group_id="O6">
            <title>End of Study: Missing the Measurement</title>
            <description>Oxycodone IR Participants who missed the measurement at the end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality: Wake up Feeling Tired and Worn Out? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</title>
          <description>Over the past 7 days patients reported &quot;Wake up feeling tired and worn out&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
          <population>Oxycodone IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="181"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="82"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1-2 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="48"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 3-5 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 6-7 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Miss the measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality: Feeling Alert During Daytime Hours? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</title>
        <description>Over the past 7 days patients reported &quot;Feeling alert during daytime hours&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
        <time_frame>Baseline and 7 Days</time_frame>
        <population>Tapentadol IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
        <group_list>
          <group group_id="O1">
            <title>End of Study: Not at All</title>
            <description>Tapentadol IR participants who chose category of 'Not at all' for the measurement at the end of study.</description>
          </group>
          <group group_id="O2">
            <title>End of Study: 1-2 Days</title>
            <description>Tapentadol IR participants who chose category of '1-2 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O3">
            <title>End of Study: 3-5 Days</title>
            <description>Tapentadol IR participants who chose category of '3-5 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O4">
            <title>End of Study: 6-7 Days</title>
            <description>Tapentadol IR participants who chose category of '6-7 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O5">
            <title>Baseline - Total</title>
            <description>Total Tapentadol IR participants at the baseline.</description>
          </group>
          <group group_id="O6">
            <title>End of Study: Missing the Measurement</title>
            <description>Tapentadol IR Participants who missed the measurement at the end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality: Feeling Alert During Daytime Hours? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</title>
          <description>Over the past 7 days patients reported &quot;Feeling alert during daytime hours&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
          <population>Tapentadol IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1-2 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 3-5 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="41"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 6-7 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="103"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Miss the measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality: Feeling Alert During Daytime Hours? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</title>
        <description>Over the past 7 days patients reported &quot;Feeling alert during daytime hours&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
        <time_frame>Baseline and 7 Days</time_frame>
        <population>Oxycodone IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
        <group_list>
          <group group_id="O1">
            <title>End of Study: Not at All</title>
            <description>Oxycodone IR participants who chose category of 'Not at all' for the measurement at the end of study.</description>
          </group>
          <group group_id="O2">
            <title>End of Study: 1-2 Days</title>
            <description>Oxycodone IR participants who chose category of '1-2 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O3">
            <title>End of Study: 3-5 Days</title>
            <description>Oxycodone IR participants who chose category of '3-5 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O4">
            <title>End of Study: 6-7 Days</title>
            <description>Oxycodone IR participants who chose category of '6-7 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O5">
            <title>Baseline - Total</title>
            <description>Total Oxycodone IR participants at the baseline.</description>
          </group>
          <group group_id="O6">
            <title>End of Study: Missing the Measurement</title>
            <description>Oxycodone IR Participants who missed the measurement at the end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality: Feeling Alert During Daytime Hours? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</title>
          <description>Over the past 7 days patients reported &quot;Feeling alert during daytime hours&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
          <population>Oxycodone IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="181"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1-2 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 3-5 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 6-7 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Miss the measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality: Feeling Well Rested? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</title>
        <description>Over the past 7 days patients reported &quot;Feeling well rested&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
        <time_frame>Baseline and 7 Days</time_frame>
        <population>Tapentadol IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
        <group_list>
          <group group_id="O1">
            <title>End of Study: Not at All</title>
            <description>Tapentadol IR participants who chose category of 'Not at all' for the measurement at the end of study.</description>
          </group>
          <group group_id="O2">
            <title>End of Study: 1-2 Days</title>
            <description>Tapentadol IR participants who chose category of '1-2 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O3">
            <title>End of Study: 3-5 Days</title>
            <description>Tapentadol IR participants who chose category of '3-5 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O4">
            <title>End of Study: 6-7 Days</title>
            <description>Tapentadol IR participants who chose category of '6-7 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O5">
            <title>Baseline - Total</title>
            <description>Total Tapentadol IR participants at the baseline.</description>
          </group>
          <group group_id="O6">
            <title>End of Study: Missing the Measurement</title>
            <description>Tapentadol IR Participants who missed the measurement at the end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality: Feeling Well Rested? - Shift of Measurement From Baseline to End of Study (Tapentadol IR)</title>
          <description>Over the past 7 days patients reported &quot;Feeling well rested&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
          <population>Tapentadol IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1-2 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 3-5 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="55"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 6-7 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="63"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Miss the measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality: Feeling Well Rested? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</title>
        <description>Over the past 7 days patients reported &quot;Feeling well rested&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
        <time_frame>Baseline and 7 Days</time_frame>
        <population>Oxycodone IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
        <group_list>
          <group group_id="O1">
            <title>End of Study: Not at All</title>
            <description>Oxycodone IR participants who chose category of 'Not at all' for the measurement at the end of study.</description>
          </group>
          <group group_id="O2">
            <title>End of Study: 1-2 Days</title>
            <description>Oxycodone IR participants who chose category of '1-2 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O3">
            <title>End of Study: 3-5 Days</title>
            <description>Oxycodone IR participants who chose category of '3-5 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O4">
            <title>End of Study: 6-7 Days</title>
            <description>Oxycodone IR participants who chose category of '6-7 Days' for the measurement at the end of study.</description>
          </group>
          <group group_id="O5">
            <title>Baseline - Total</title>
            <description>Total Oxycodone IR participants at the baseline.</description>
          </group>
          <group group_id="O6">
            <title>End of Study: Missing the Measurement</title>
            <description>Oxycodone IR Participants who missed the measurement at the end of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality: Feeling Well Rested? - Shift of Measurement From Baseline to End of Study (Oxycodone IR)</title>
          <description>Over the past 7 days patients reported &quot;Feeling well rested&quot; by using a 4-category scale (not at all, 1 to 2 days, 3 to 5 days, 6 to 7 days) at baseline and the final study visit (Day 7).</description>
          <population>Oxycodone IR arm of Intent-to-Treat population. Shift table from baseline to end of study (Day 7).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="181"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1-2 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 3-5 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 6-7 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="70"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Miss the measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tapentadol IR</title>
          <description>Tapentadol IR 50 or 100 mg 4-6 hours as needed; maximum 600mg a day for 7 days but can be up 9 days</description>
        </group>
        <group group_id="E2">
          <title>Oxycodone IR</title>
          <description>Oxycodone IR 5 or 10 mg 4-6 hours as needed, maximum 60 mg a day for 7 days but can be up to 9 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis Superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No notable study limitations were identified by the Sponsor</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Director of Clinical Development, Pain</name_or_title>
      <organization>Ortho-McNeil Janssen Scientific Affair, LLC</organization>
      <phone>(908)927-5469</phone>
      <email>GVorsang@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

